Factor VII TRIZ Cases
- CpG-Reduced Promoters for AAV Vector Packaging
CpG-reduced promoter sequences reduce untranslated nucleic acid content to improve vector packaging efficiency and Factor VIII-BDD expression levels.
- Factor VIII Activation Antibody for Hemophilia A Treatment
Antibody moAb216 extends Factor VIII half-life and reduces inhibitor interference by modifying cleavage patterns.
- PEGylated FVIII-Fc Fusion Protein Half-Life Extension
Optimizing polyethylene glycol modification parameters balances extended circulation time with preserved coagulation activity.
- Non-AAV ITR Nucleic Acid Molecules for Hemophilia Gene Therapy
Replacing adeno-associated virus inverted terminal repeats with non-adeno-associated virus sequences eliminates immune responses and expands packaging capacity.
- Synthetic Liver Promoters and BDD-FVIII for AAV Packaging
Minimal synthetic promoters and B-domain deleted Factor VIII fit adeno-associated virus packaging limits while sustaining long-term hemostatic control.
- In Utero Transplanted Modified MSC for Hemophilia A Treatment
Prenatal transplantation of genetically modified mesenchymal stem cells establishes lifelong Factor VIII production, eliminating lifelong infusion requirements.
- Synthetic FVIII B Domain Substitute for Hemophilia A Gene Editing
A synthetic Factor VIII coding sequence with a modified B domain substitute enables stable genomic integration via gene editing.
- Glycoprotein Production via Manganese-Controlled Culture Media
Optimizing manganese and glutamine concentrations in defined media resolves the contradiction between high productivity and precise glycosylation quality.